US academic drug discovery

Nature Reviews Drug Discovery

Volumn 10, Issue 6, 2011, Pages 409-410

  Frye, Stephen ^a   Crosby, Marina ^b   Edwards, Teresa ^b   Juliano, Rudolph ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; DRUG EFFICACY; DRUG INDUSTRY; DRUG METABOLISM; DRUG RESEARCH; FINANCIAL MANAGEMENT; FUNDING; HEALTH SURVEY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; UNITED STATES; VALIDATION PROCESS;

ACADEMIC MEDICAL CENTERS; DRUG DISCOVERY; HUMANS; UNITED STATES; UNIVERSITIES;

EID: 79957898111     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3462     Document Type: Article

References (5)

1. Wyatt, P. G. The emerging academic drug-discovery sector. Future Med. Chem. 1, 1013-1017 (2009).
2. Tralau-Stewart, C J. et al. Drug discovery: new models for industry-academic partnerships. Drug Discov. Today 14, 95-101 (2009).
3. Edwards, A. M. et al. Open access chemical and clinical probes to support drug discovery. Nature Chem. Biol. 5, 436-440 (2009).
4. Kneller, R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Rev. Drug Discov. 9, 867-882 (2010).
5. Stevens, A. J. et al. The role of public-sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364, 535-541 (2011).